INMB Quote, Financials, Valuation and Earnings

Omeros Corp. has a net margin of -19478% compared to INmune Bio, Inc.'s net margin of --. INmune Bio, Inc.'s return on equity of -161.25% beat Omeros Corp.'s return on equity of --.

INmune Bio, Inc. has a consensus price target of $7.00, signalling upside risk potential of 478.51%. On the other hand Omeros Corp. has an analysts' consensus of $38.00 which suggests that it could grow by 248.62%. Given that INmune Bio, Inc. has higher upside potential than Omeros Corp., analysts believe INmune Bio, Inc. is more attractive than Omeros Corp..

INmune Bio, Inc. has a beta of 0.882, which suggesting that the stock is 11.841% less volatile than S&P 500. In comparison Omeros Corp. has a beta of 2.529, suggesting its more volatile than the S&P 500 by 152.947%.

INmune Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. INmune Bio, Inc. pays -- of its earnings as a dividend. Omeros Corp. pays out -- of its earnings as a dividend.

INmune Bio, Inc. quarterly revenues are --, which are smaller than Omeros Corp. quarterly revenues of --. INmune Bio, Inc.'s net income of -$6.5M is higher than Omeros Corp.'s net income of -$21.2M. Notably, INmune Bio, Inc.'s price-to-earnings ratio is -- while Omeros Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for INmune Bio, Inc. is 598.74x versus -- for Omeros Corp.. Usually stocks with elevated PS ratios are considered overvalued.

PDS Biotechnology Corp. has a net margin of -19478% compared to INmune Bio, Inc.'s net margin of --. INmune Bio, Inc.'s return on equity of -161.25% beat PDS Biotechnology Corp.'s return on equity of -196.47%.

INmune Bio, Inc. has a consensus price target of $7.00, signalling upside risk potential of 478.51%. On the other hand PDS Biotechnology Corp. has an analysts' consensus of $7.50 which suggests that it could grow by 1317.32%. Given that PDS Biotechnology Corp. has higher upside potential than INmune Bio, Inc., analysts believe PDS Biotechnology Corp. is more attractive than INmune Bio, Inc..

INmune Bio, Inc. has a beta of 0.882, which suggesting that the stock is 11.841% less volatile than S&P 500. In comparison PDS Biotechnology Corp. has a beta of 1.196, suggesting its more volatile than the S&P 500 by 19.619%.

INmune Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PDS Biotechnology Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. INmune Bio, Inc. pays -- of its earnings as a dividend. PDS Biotechnology Corp. pays out -- of its earnings as a dividend.

INmune Bio, Inc. quarterly revenues are --, which are smaller than PDS Biotechnology Corp. quarterly revenues of --. INmune Bio, Inc.'s net income of -$6.5M is higher than PDS Biotechnology Corp.'s net income of -$9M. Notably, INmune Bio, Inc.'s price-to-earnings ratio is -- while PDS Biotechnology Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for INmune Bio, Inc. is 598.74x versus -- for PDS Biotechnology Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Precipio, Inc. has a net margin of -19478% compared to INmune Bio, Inc.'s net margin of -1.17%. INmune Bio, Inc.'s return on equity of -161.25% beat Precipio, Inc.'s return on equity of -10.15%.

INmune Bio, Inc. has a consensus price target of $7.00, signalling upside risk potential of 478.51%. On the other hand Precipio, Inc. has an analysts' consensus of -- which suggests that it could fall by -25.2%. Given that INmune Bio, Inc. has higher upside potential than Precipio, Inc., analysts believe INmune Bio, Inc. is more attractive than Precipio, Inc..

INmune Bio, Inc. has a beta of 0.882, which suggesting that the stock is 11.841% less volatile than S&P 500. In comparison Precipio, Inc. has a beta of 1.194, suggesting its more volatile than the S&P 500 by 19.441%.

INmune Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precipio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. INmune Bio, Inc. pays -- of its earnings as a dividend. Precipio, Inc. pays out -- of its earnings as a dividend.

INmune Bio, Inc. quarterly revenues are --, which are smaller than Precipio, Inc. quarterly revenues of $6.8M. INmune Bio, Inc.'s net income of -$6.5M is lower than Precipio, Inc.'s net income of -$79K. Notably, INmune Bio, Inc.'s price-to-earnings ratio is -- while Precipio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for INmune Bio, Inc. is 598.74x versus 1.72x for Precipio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sangamo Therapeutics, Inc. has a net margin of -19478% compared to INmune Bio, Inc.'s net margin of -6012.05%. INmune Bio, Inc.'s return on equity of -161.25% beat Sangamo Therapeutics, Inc.'s return on equity of -587.71%.

INmune Bio, Inc. has a consensus price target of $7.00, signalling upside risk potential of 478.51%. On the other hand Sangamo Therapeutics, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 1149.58%. Given that Sangamo Therapeutics, Inc. has higher upside potential than INmune Bio, Inc., analysts believe Sangamo Therapeutics, Inc. is more attractive than INmune Bio, Inc..

INmune Bio, Inc. has a beta of 0.882, which suggesting that the stock is 11.841% less volatile than S&P 500. In comparison Sangamo Therapeutics, Inc. has a beta of 1.494, suggesting its more volatile than the S&P 500 by 49.424%.

INmune Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sangamo Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. INmune Bio, Inc. pays -- of its earnings as a dividend. Sangamo Therapeutics, Inc. pays out -- of its earnings as a dividend.

INmune Bio, Inc. quarterly revenues are --, which are smaller than Sangamo Therapeutics, Inc. quarterly revenues of $581K. INmune Bio, Inc.'s net income of -$6.5M is higher than Sangamo Therapeutics, Inc.'s net income of -$34.9M. Notably, INmune Bio, Inc.'s price-to-earnings ratio is -- while Sangamo Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for INmune Bio, Inc. is 598.74x versus 2.12x for Sangamo Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.